Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein.
Identifieur interne : 001366 ( PubMed/Checkpoint ); précédent : 001365; suivant : 001367Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein.
Auteurs : Dharmendra Raghuwanshi [Canada] ; Vivek Mishra ; Dipankar Das ; Kamaljit Kaur ; Mavanur R. SureshSource :
- Molecular pharmaceutics [ 1543-8392 ] ; 2012.
Descripteurs français
- KwdFr :
- MESH :
- immunologie : Immunité humorale, Protéines nucléocapside, Vaccins antiviraux, Vaccins à ADN, Virus du SRAS.
- métabolisme : Cellules dendritiques.
- Animaux, Chitosane, Femelle, Nanoparticules, Souris, Souris de lignée BALB C.
English descriptors
- KwdEn :
- MESH :
- chemical , chemistry : Chitosan.
- chemistry : Nanoparticles.
- immunology : Immunity, Humoral, Nucleocapsid Proteins, SARS Virus, Vaccines, DNA, Viral Vaccines.
- metabolism : Dendritic Cells.
- Animals, Female, Mice, Mice, Inbred BALB C.
Abstract
This work investigates the formulation and in vivo efficacy of dendritic cell (DC) targeted plasmid DNA loaded biotinylated chitosan nanoparticles for nasal immunization against nucleocapsid (N) protein of severe acute respiratory syndrome coronavirus (SARS-CoV) as antigen. The induction of antigen-specific mucosal and systemic immune response at the site of virus entry is a major challenge for vaccine design. Here, we designed a strategy for noninvasive receptor mediated gene delivery to nasal resident DCs. The pDNA loaded biotinylated chitosan nanoparticles were prepared using a complex coacervation process and characterized for size, shape, surface charge, plasmid DNA loading and protection against nuclease digestion. The pDNA loaded biotinylated chitosan nanoparticles were targeted with bifunctional fusion protein (bfFp) vector for achieving DC selective targeting. The bfFp is a recombinant fusion protein consisting of truncated core-streptavidin fused with anti-DEC-205 single chain antibody (scFv). The core-streptavidin arm of fusion protein binds with biotinylated nanoparticles, while anti-DEC-205 scFv imparts targeting specificity to DC DEC-205 receptor. We demonstrate that intranasal administration of bfFp targeted formulations along with anti-CD40 DC maturation stimuli enhanced magnitude of mucosal IgA as well as systemic IgG against N protein. The strategy led to the detection of augmented levels of N protein specific systemic IgG and nasal IgA antibodies. However, following intranasal delivery of naked pDNA no mucosal and systemic immune responses were detected. A parallel comparison of targeted formulations using intramuscular and intranasal routes showed that the intramuscular route is superior for induction of systemic IgG responses compared with the intranasal route. Our results suggest that targeted pDNA delivery through a noninvasive intranasal route can be a strategy for designing low-dose vaccines.
DOI: 10.1021/mp200553x
PubMed: 22356166
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:22356166Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein.</title><author><name sortKey="Raghuwanshi, Dharmendra" sort="Raghuwanshi, Dharmendra" uniqKey="Raghuwanshi D" first="Dharmendra" last="Raghuwanshi">Dharmendra Raghuwanshi</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta , Edmonton, Alberta T6G 2N8, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta , Edmonton, Alberta T6G 2N8</wicri:regionArea><wicri:noRegion>Alberta T6G 2N8</wicri:noRegion></affiliation></author><author><name sortKey="Mishra, Vivek" sort="Mishra, Vivek" uniqKey="Mishra V" first="Vivek" last="Mishra">Vivek Mishra</name></author><author><name sortKey="Das, Dipankar" sort="Das, Dipankar" uniqKey="Das D" first="Dipankar" last="Das">Dipankar Das</name></author><author><name sortKey="Kaur, Kamaljit" sort="Kaur, Kamaljit" uniqKey="Kaur K" first="Kamaljit" last="Kaur">Kamaljit Kaur</name></author><author><name sortKey="Suresh, Mavanur R" sort="Suresh, Mavanur R" uniqKey="Suresh M" first="Mavanur R" last="Suresh">Mavanur R. Suresh</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22356166</idno><idno type="pmid">22356166</idno><idno type="doi">10.1021/mp200553x</idno><idno type="wicri:Area/PubMed/Corpus">001393</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001393</idno><idno type="wicri:Area/PubMed/Curation">001393</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001393</idno><idno type="wicri:Area/PubMed/Checkpoint">001366</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001366</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein.</title><author><name sortKey="Raghuwanshi, Dharmendra" sort="Raghuwanshi, Dharmendra" uniqKey="Raghuwanshi D" first="Dharmendra" last="Raghuwanshi">Dharmendra Raghuwanshi</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta , Edmonton, Alberta T6G 2N8, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta , Edmonton, Alberta T6G 2N8</wicri:regionArea><wicri:noRegion>Alberta T6G 2N8</wicri:noRegion></affiliation></author><author><name sortKey="Mishra, Vivek" sort="Mishra, Vivek" uniqKey="Mishra V" first="Vivek" last="Mishra">Vivek Mishra</name></author><author><name sortKey="Das, Dipankar" sort="Das, Dipankar" uniqKey="Das D" first="Dipankar" last="Das">Dipankar Das</name></author><author><name sortKey="Kaur, Kamaljit" sort="Kaur, Kamaljit" uniqKey="Kaur K" first="Kamaljit" last="Kaur">Kamaljit Kaur</name></author><author><name sortKey="Suresh, Mavanur R" sort="Suresh, Mavanur R" uniqKey="Suresh M" first="Mavanur R" last="Suresh">Mavanur R. Suresh</name></author></analytic><series><title level="j">Molecular pharmaceutics</title><idno type="eISSN">1543-8392</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Chitosan (chemistry)</term><term>Dendritic Cells (metabolism)</term><term>Female</term><term>Immunity, Humoral (immunology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Nanoparticles (chemistry)</term><term>Nucleocapsid Proteins (immunology)</term><term>SARS Virus (immunology)</term><term>Vaccines, DNA (immunology)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Cellules dendritiques (métabolisme)</term><term>Chitosane ()</term><term>Femelle</term><term>Immunité humorale (immunologie)</term><term>Nanoparticules ()</term><term>Protéines nucléocapside (immunologie)</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins à ADN (immunologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Chitosan</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Nanoparticles</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Immunité humorale</term><term>Protéines nucléocapside</term><term>Vaccins antiviraux</term><term>Vaccins à ADN</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Immunity, Humoral</term><term>Nucleocapsid Proteins</term><term>SARS Virus</term><term>Vaccines, DNA</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Dendritic Cells</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cellules dendritiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Female</term><term>Mice</term><term>Mice, Inbred BALB C</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Chitosane</term><term>Femelle</term><term>Nanoparticules</term><term>Souris</term><term>Souris de lignée BALB C</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This work investigates the formulation and in vivo efficacy of dendritic cell (DC) targeted plasmid DNA loaded biotinylated chitosan nanoparticles for nasal immunization against nucleocapsid (N) protein of severe acute respiratory syndrome coronavirus (SARS-CoV) as antigen. The induction of antigen-specific mucosal and systemic immune response at the site of virus entry is a major challenge for vaccine design. Here, we designed a strategy for noninvasive receptor mediated gene delivery to nasal resident DCs. The pDNA loaded biotinylated chitosan nanoparticles were prepared using a complex coacervation process and characterized for size, shape, surface charge, plasmid DNA loading and protection against nuclease digestion. The pDNA loaded biotinylated chitosan nanoparticles were targeted with bifunctional fusion protein (bfFp) vector for achieving DC selective targeting. The bfFp is a recombinant fusion protein consisting of truncated core-streptavidin fused with anti-DEC-205 single chain antibody (scFv). The core-streptavidin arm of fusion protein binds with biotinylated nanoparticles, while anti-DEC-205 scFv imparts targeting specificity to DC DEC-205 receptor. We demonstrate that intranasal administration of bfFp targeted formulations along with anti-CD40 DC maturation stimuli enhanced magnitude of mucosal IgA as well as systemic IgG against N protein. The strategy led to the detection of augmented levels of N protein specific systemic IgG and nasal IgA antibodies. However, following intranasal delivery of naked pDNA no mucosal and systemic immune responses were detected. A parallel comparison of targeted formulations using intramuscular and intranasal routes showed that the intramuscular route is superior for induction of systemic IgG responses compared with the intranasal route. Our results suggest that targeted pDNA delivery through a noninvasive intranasal route can be a strategy for designing low-dose vaccines.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22356166</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1543-8392</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Apr</Month><Day>02</Day></PubDate></JournalIssue><Title>Molecular pharmaceutics</Title><ISOAbbreviation>Mol. Pharm.</ISOAbbreviation></Journal><ArticleTitle>Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein.</ArticleTitle><Pagination><MedlinePgn>946-56</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/mp200553x</ELocationID><Abstract><AbstractText>This work investigates the formulation and in vivo efficacy of dendritic cell (DC) targeted plasmid DNA loaded biotinylated chitosan nanoparticles for nasal immunization against nucleocapsid (N) protein of severe acute respiratory syndrome coronavirus (SARS-CoV) as antigen. The induction of antigen-specific mucosal and systemic immune response at the site of virus entry is a major challenge for vaccine design. Here, we designed a strategy for noninvasive receptor mediated gene delivery to nasal resident DCs. The pDNA loaded biotinylated chitosan nanoparticles were prepared using a complex coacervation process and characterized for size, shape, surface charge, plasmid DNA loading and protection against nuclease digestion. The pDNA loaded biotinylated chitosan nanoparticles were targeted with bifunctional fusion protein (bfFp) vector for achieving DC selective targeting. The bfFp is a recombinant fusion protein consisting of truncated core-streptavidin fused with anti-DEC-205 single chain antibody (scFv). The core-streptavidin arm of fusion protein binds with biotinylated nanoparticles, while anti-DEC-205 scFv imparts targeting specificity to DC DEC-205 receptor. We demonstrate that intranasal administration of bfFp targeted formulations along with anti-CD40 DC maturation stimuli enhanced magnitude of mucosal IgA as well as systemic IgG against N protein. The strategy led to the detection of augmented levels of N protein specific systemic IgG and nasal IgA antibodies. However, following intranasal delivery of naked pDNA no mucosal and systemic immune responses were detected. A parallel comparison of targeted formulations using intramuscular and intranasal routes showed that the intramuscular route is superior for induction of systemic IgG responses compared with the intranasal route. Our results suggest that targeted pDNA delivery through a noninvasive intranasal route can be a strategy for designing low-dose vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raghuwanshi</LastName><ForeName>Dharmendra</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta , Edmonton, Alberta T6G 2N8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mishra</LastName><ForeName>Vivek</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Dipankar</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Kaur</LastName><ForeName>Kamaljit</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Suresh</LastName><ForeName>Mavanur R</ForeName><Initials>MR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AI061233-04</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Pharm</MedlineTA><NlmUniqueID>101197791</NlmUniqueID><ISSNLinking>1543-8384</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019590">Nucleocapsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>9012-76-4</RegistryNumber><NameOfSubstance UI="D048271">Chitosan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048271" MajorTopicYN="N">Chitosan</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003713" MajorTopicYN="N">Dendritic Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019590" MajorTopicYN="N">Nucleocapsid Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22356166</ArticleId><ArticleId IdType="doi">10.1021/mp200553x</ArticleId><ArticleId IdType="pmc">PMC3322645</ArticleId><ArticleId IdType="mid">NIHMS359949</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mol Pharm. 2007 Jan-Feb;4(1):58-72</Citation><ArticleIdList><ArticleId IdType="pubmed">17228857</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2006 Mar 30;347(1):127-39</Citation><ArticleIdList><ArticleId IdType="pubmed">16387339</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Cell Biol. 2007 Apr-May;85(3):182-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17262055</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 2007 May 28;26(25):3758-67</Citation><ArticleIdList><ArticleId IdType="pubmed">17530028</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2007 Oct;7(10):790-802</Citation><ArticleIdList><ArticleId IdType="pubmed">17853902</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomaterials. 2008 Apr;29(12):1931-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18221992</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Pharm. 2008 Apr 16;354(1-2):235-41</Citation><ArticleIdList><ArticleId IdType="pubmed">18182259</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Genet Evol. 2008 Jul;8(4):397-405</Citation><ArticleIdList><ArticleId IdType="pubmed">17881296</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol Methods. 2008 Sep;152(1-2):77-84</Citation><ArticleIdList><ArticleId IdType="pubmed">18620761</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2008 Sep 19;29(3):319-24</Citation><ArticleIdList><ArticleId IdType="pubmed">18799140</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Genet. 2008 Oct;9(10):776-88</Citation><ArticleIdList><ArticleId IdType="pubmed">18781156</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharm. 2009 Jan-Feb;6(1):158-72</Citation><ArticleIdList><ArticleId IdType="pubmed">19053535</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Drug Deliv Rev. 2009 Feb 27;61(2):140-57</Citation><ArticleIdList><ArticleId IdType="pubmed">19121350</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Dec 2;26(51):6678-84</Citation><ArticleIdList><ArticleId IdType="pubmed">18805454</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Rev. 2009 May;229(1):152-72</Citation><ArticleIdList><ArticleId IdType="pubmed">19426221</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2009 Jul;8(7):887-98</Citation><ArticleIdList><ArticleId IdType="pubmed">19538115</ArticleId></ArticleIdList></Reference><Reference><Citation>Biotechnol Adv. 2009 Nov-Dec;27(6):857-65</Citation><ArticleIdList><ArticleId IdType="pubmed">19583998</ArticleId></ArticleIdList></Reference><Reference><Citation>Recent Pat Drug Deliv Formul. 2010 Jun;4(2):114-28</Citation><ArticleIdList><ArticleId IdType="pubmed">20380624</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Vaccine Immunol. 2011 Jan;18(1):75-81</Citation><ArticleIdList><ArticleId IdType="pubmed">21047997</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomaterials. 2011 Sep;32(26):6164-73</Citation><ArticleIdList><ArticleId IdType="pubmed">21641031</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2006 Aug 1;351(2):466-75</Citation><ArticleIdList><ArticleId IdType="pubmed">16690096</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 2000 Oct 30;151(3):673-84</Citation><ArticleIdList><ArticleId IdType="pubmed">11062267</ArticleId></ArticleIdList></Reference><Reference><Citation>J Control Release. 2001 Feb 23;70(3):399-421</Citation><ArticleIdList><ArticleId IdType="pubmed">11182210</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2002 Aug 19;20(25-26):3123-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12163263</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2002 Dec 16;196(12):1627-38</Citation><ArticleIdList><ArticleId IdType="pubmed">12486105</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomaterials. 2003 Mar;24(7):1255-64</Citation><ArticleIdList><ArticleId IdType="pubmed">12527266</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2004 Mar 15;199(6):815-24</Citation><ArticleIdList><ArticleId IdType="pubmed">15024047</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 May;78(9):4638-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15078946</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Lett. 2004 Apr 15;92(3):237-43</Citation><ArticleIdList><ArticleId IdType="pubmed">15081618</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1995 May 11;375(6527):151-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7753172</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol Methods. 2006 Nov;137(2):343-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16904198</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Immunol. 1995 Jun;163(1):148-56</Citation><ArticleIdList><ArticleId IdType="pubmed">7758125</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Immunol. 1995 Jun;163(1):157-62</Citation><ArticleIdList><ArticleId IdType="pubmed">7758126</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2004 Nov;114(9):1241-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15520855</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Virol. 2004 Dec;31 Suppl 1:S99-106</Citation><ArticleIdList><ArticleId IdType="pubmed">15567101</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2005 Jan 5;331(1):128-35</Citation><ArticleIdList><ArticleId IdType="pubmed">15582659</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol Methods. 2005 Nov 30;306(1-2):80-92</Citation><ArticleIdList><ArticleId IdType="pubmed">16202424</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2006 Mar;87(Pt 3):641-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16476986</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2006 Mar 20;203(3):607-17</Citation><ArticleIdList><ArticleId IdType="pubmed">16505141</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharm Biopharm. 2007 Mar;65(3):398-405</Citation><ArticleIdList><ArticleId IdType="pubmed">17257818</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Das, Dipankar" sort="Das, Dipankar" uniqKey="Das D" first="Dipankar" last="Das">Dipankar Das</name><name sortKey="Kaur, Kamaljit" sort="Kaur, Kamaljit" uniqKey="Kaur K" first="Kamaljit" last="Kaur">Kamaljit Kaur</name><name sortKey="Mishra, Vivek" sort="Mishra, Vivek" uniqKey="Mishra V" first="Vivek" last="Mishra">Vivek Mishra</name><name sortKey="Suresh, Mavanur R" sort="Suresh, Mavanur R" uniqKey="Suresh M" first="Mavanur R" last="Suresh">Mavanur R. Suresh</name></noCountry><country name="Canada"><noRegion><name sortKey="Raghuwanshi, Dharmendra" sort="Raghuwanshi, Dharmendra" uniqKey="Raghuwanshi D" first="Dharmendra" last="Raghuwanshi">Dharmendra Raghuwanshi</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001366 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001366 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:22356166
|texte= Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:22356166" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |